Macrophage-fibroblast communication driven by biomechanical stress in the pulmonary profibrotic niche: From signalling transduction to clinical translation. (PubMed, Cells Dev) - Sep 23, 2026 - "The three approved antifibrotic agents - pirfenidone, nintedanib, and nerandomilast - receive only moderate endorsements in current guidelines, as they decelerate rather than arrest or reverse fibrotic remodelling, and none directly engages the mechanical dysregulation of the extracellular matrix (ECM) that underlies fibrogenesis. Finally, we discuss the clinical translation of mechanosignalling-targeted antifibrotic therapies, from the limited mechanosensing engagement of approved drugs to current pipeline advances and the preclinical and clinical hurdles ahead. By framing fibrosis as a druggable biomechanical circuit, this review aims to inform strategies that halt - and potentially reverse - pulmonary fibrosis."
Journal • Review • Fibrosis • Immunology • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases
|
|
Hong Yang; Liya Ye; Wansheng Chen; Xia Tao; Xingyun Hou; Yuqiong He
|